Abnormal activation the WNT/ȕ-catenin signaling pathway has been associated with ovarian carcinomas, but a specific WNT ligand and pertinent downstream mechanisms are not fully understood. In this study, we found abundant WNT7A in the epithelium of serous ovarian carcinomas, but not detected in borderline and benign tumors, normal ovary or endometrioid carcinomas. To characterize the role of WNT7A in ovarian tumor growth and progression, nude mice were injected either intraperitoneally (i.p.) or subcutaneously (s.c.) with WNT7A knocked down SKOV3.ip1 and overexpressed SKOV3 cells. In the i.p. group, mice receiving SKOV3.ip1 cells with reduced WNT7A expression developed significantly fewer tumor lesions. Gross and histological examination revealed greatly reduced invasion of WNT7A knockdown cells into intestinal mesentery and serosa compared to the control cells. Tumor growth was regulated by loss or overexpression of WNT7A in mice receiving s.c. injection as well. In vitro analysis of cell function revealed that cell proliferation, adhesion, and invasion were regulated by WNT7A.
Introduction
Ovarian cancer remains the most common cause of death from a gynecological malignancy and is the fifth leading overall cause of death from cancer in women (1) . Epithelial ovarian cancer (EOC) constitutes more than 90% of ovarian malignancies (2) . The high mortality related to EOC is thought to be due to the advanced stage of the disease at presentation. Unlike most carcinomas that dedifferentiate during neoplastic progression, ovarian carcinomas undergo transition to a more epithelial phenotype early in tumor progression. Thus, identification of novel diagnostic and prognostic factors in EOC can aid in predicting clinical outcome.
WNT genes encode secreted glycoproteins acting through frizzled receptor (FZD) that control cell fate, mortality, proliferation, differentiation (3, 4) and tissue growth (5) . WNT was initially discovered as a proto-oncogene in mammary tumors activated by integration of the mouse mammary tumor virus (6) . The WNT pathway promotes ovarian cancer progression via diverse mechanisms including gene mutations and changes in expression of extracellular inhibitors and intranuclear transcription cofactors. The canonical pathway of WNT signaling results in ȕ-catenin nuclear accumulation and transcriptional activation of target genes. In the presence of WNTs, cytoplasmic ȕ-catenin is stabilized by inhibition of GSK3ȕ, translocated to the nucleus where it associates with LEF/TCF transcription factors, and induces c-myc, cyclinD and MMP7 (7) (8) (9) . It has been established that the WNT pathway is often constitutively activated, usually via missense mutation of CTNNB1 (ȕ-catenin), in the endometrioid histopathologic type of ovarian carcinomas. These mutations typically alter residues phosphorylated by GSK3ȕ, and hence, ȕ-catenin protein cannot be targeted for degradation, leading to deregulation of the pathway and transcription of target genes, which are likely important for neoplastic transformation and tumor progression (10) . Endometrioid adenocarcinomas with deregulated WNT signaling show nuclear accumulation of ȕ-catenin whereas tumors with intact WNT signaling show only stromal and membrane-bound ȕ-catenin (10, 11) . However, nuclear localization of ȕ-catenin was also observed in high percentage of both low-and high-grade serous carcinomas (12) , suggesting that the WNT/ȕ-catenin pathway can be activated in other categories of EOC without mutation of ȕ-catenin. However, the identity and the clinical significance of the ligand partners associated with WNT signaling in ovarian cancer are currently unknown.
We focused on one of Wnt ligands, WNT7A, for several reasons. In the female reproductive tract, WNT7A is exclusively expressed in epithelial cells (13) (14) (15) (16) (17) and acts via FZD in the mesenchyme and epithelium. In rodents, Wnt7a regulates a variety of cellular and developmental pathways that direct prenatal growth of the female reproductive tract and maintain proper uterine function (14) . Further, WNT7A increases cell proliferation via activation of the canonical WNT/ȕ-catenin pathway (18, 19) . In endometrial carcinomas, WNT7A acting via ȕ-catenin signaling induces cell proliferation (20) , where SFRP4 (a WNT receptor antagonist) suppresses the activity of WNT7A leading to inhibition of cell division (21) .
While WNT7A dependent regulation of cell proliferation and adhesion in other tissues and tumors has been reported, the role of WNT7A in ovarian cancer has not been examined due to the absence of WNT7A in normal ovary.
In the present study, we found that WNT7A is not expressed in normal adult ovarian tissues, but is highly and frequently expressed in a large panel of human malignant ovarian tumors. We also determined in an orthotopic xenograft model that suppression of WNT7A in an ovarian carcinoma line SKOV3.ip1 severely restricts establishment of tumor lesions as well as their spread throughout the peritoneal cavity. This result was supported by overexpression of WNT7A in SKOV3 cells. In vitro analyses showed that WNT7A controls proliferation, adhesion, invasion, and cell cycle of ovarian cancer cells. These effects were accompanied by up-regulation of MMP7 and cyclin D1, two known transcriptional targets of the canonical ȕ-catenin/TCF pathway. Collectively, these data demonstrate overexpression of WNT7A in human ovarian cancer, and suggest an important role for this ligand in progression of ovarian malignancies.
Materials and Methods

Tissue samples and cell lines
A total of 300 paraffin-embedded and 18 fresh-frozen tumor, benign/borderline and normal ovarian specimens were obtained from the tissue bank at Southern Illinois University School of Medicine Simmons Cancer Institute and US Biomax (Rockville, MD). Histopathological typing was verified for each section by a gynecological oncology pathologist. Human ovarian cancer cell lines: OVCAR3, SKOV3, TOV-112D, TOV-21G. OV-90, MDAH 2774 and ES2 were purchased from ATCC. A2780 was purchased from Sigma. HEY, HEYA8, OVCAR8, OVCA420, OVCA429, OVCA432 and OVCA433 were purchased from the cell bank of The University of Texas MD Anderson cancer center. All experiments using these cell lines were done within 4 months after receipt. SKOV3.ip.1 and IGROV-1 cells were kindly provided by Dr. Judith Wolf of The University of Texas MD Anderson cancer center and Dr. Laurent Brard Southern Illinois University School of Medicine, respectively. SKOV3.ip1 and IGROV-1 cell lines were initially characterized and described in Cancer Research (22) and (23), respectively. The cells used were from passage 14 and 21 of the original clone. The cells were characterized by measuring the expression of genes (all 19 WNT genes, MMP7, MMP9) and active ȕ-catenin in nuclear extracts.
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The expression was consistent with the data from the original clone. All cells were tested routinely for cell proliferation and BrdU incorporation as well as mycoplasma contamination, and they showed similar growth rate and negative mycoplasma during the experiment. TOV-112D, TOV-21G, and OV-90 cells were grown in 1:1 MCDB 105:M199 with 15% FBS and penicillin/streptomycin, other cells were cultured in DMEM with 10% FBS, 200mM glutamine and penicillin/streptomycin. All cell lines were grown at 37 °C in a humidified 5% CO 2 incubator.
RNA expression analyses
Total RNA was isolated from human tissues and cells, and cDNA was synthesized from total RNA. Relative gene expression was determined by SYBR green incorporation in a BioRad myCycler as described previously (16) . A table of oligonucleotides used for each gene is present in Supplementary Table S1 . In situ hybridization analysis of human ovarian tissues was conducted using methods described previously (24) .
Western blot analysis
Thirty micrograms of total protein from whole cell lysates, or ten micrograms nuclear or cytoplasmic protein extract were separated on SDS-PAGE gels and transferred to nitrocellulose membranes (Millipore). Membranes were blocked and incubated overnight at 4°C with primary antibodies: anti-WNT7A (#HPA015719) from Sigma-Aldrich, anti-MMP7 (#05-665) and antiactive ȕ-catenin (#MAB3315) from Millipore, anti-ȕ-catenin (#610153) from BD Biosciences, anti-cyclin D1 (#RM-9104-S1) from Thermo Fisher, and anti-GAPDH (#3073) and anti-actin (#5401) from IMGENEX. Bound antibody was visualized with IRDye 700 or 800 conjugated affinity-purified secondary antibodies (Rockland Immunochemicals) using the Odyssey infrared imaging system (LI-COR).
Cell proliferation assay
To assess cell proliferation, cells (2 x 10 4 /well) were seeded in 24-well plates and cultured in DMEM without serum for 20 h. During this incubation, cells attached to the substratum but did not proliferate. After serum-starvation for 20 h, 3 wells were harvested, stained with trypan blue to assess viability, and counted using an automated cell counter TC10
(BioRad) to serve as 0 h control. Cells in parallel wells were cultured with normal growth medium at 37 °C for 24, 48 or 72 h, and then stained with trypan blue and counted as above. In addition to counting total cell numbers, BrdU incorporation during DNA synthesis was measured after 48 h culture with growth medium following manufacturer's recommendations (Roche applied Science). Doubling time of cells was calculated from the growth rate during the exponential growth phase (0-72 h) using the formula, Td = 0.693t / ln(N t /N 0 ), where t is time in days, N t is cell number at time t, and N 0 is cell number at initial time (25, 26) .
Cell cycle assay
Cells (1 x 10 5 /well) were seeded in 6 well plates in DMEM without serum for 20 h.
Synchronized cells were then cultured in growth medium for 24 h or 48 h for SKOV3.ip.1 and SKOV3 cells, respectively, before collection by trypsinization and centrifugation. Cell pellets washed with ice cold PBS were suspended in 0.5% Triton X-100 in PBS containing RNase A and propidium iodide, and incubated for 15 min on ice. Fluorescent emission was quantified by
FACScan cytometry (Beckman Coulter CellQuanta). 20 min at room temperature as described previously (27) . The plate was immersed in water and destained by gentle shaking. Stained cells were immediately lysed in 100 μl of 2N NaOH followed by reading absorbance at 595 nm using a microplate reader (BioTek Synergy HT).
Cell invasion assay
Cell invasion assays were performed using a modified Boyden Chamber method with 8-μm pore size polycarbonate membrane 24-well transwells coated with matrigel (Corning), as previously described (18, 28, 29) . Cells were serum-starved in DMEM for 20 h, dislodged, and re-plated in the upper well at a density of 75 x 10 3 cells per well in 100 μl of serum-free medium.
After 24 h, cells remaining on the upper surface of the membrane were wiped off with a cotton swab. For evaluation of invading cells on the lower surface, inserts were fixed in 4% paraformaldehyde for 3 min. Transwell membranes were then removed and stained with DAPI.
Invading cells were counted in five non-overlapping fields, which covered approximately 70% of the insert membrane area, using a Leica DM5000B photomicroscope. The results are presented as the mean number of invading cells per field ± SEM. 
CTNNB1 mutation analysis
DNA from fixed tissues was isolated using QIAamp DNA FFPE Tissue Kit (56404). Exon 3 has previously been shown to harbor mutations at codons 33, 34 and 37 in endometrioid ovarian cancer. To assess for these mutations in our samples, we amplified this region using primers: Forward, 5'-CGTGGACAATGGCTACTCAA -3' and Reverse 5'-TGCATACTGTCCATCAATA -3' (31). Each PCR fragment was purified and sequenced using a Beckman CEQ 8000 DNA sequencer with GenomeLab™ DTCS Quick Start Kit and the following primer 5'-GGAGTTGGACATGGCCATGGAA -3'. Sequencing reactions were repeated for all samples.
Statistical analyses
Chi-square tests were used to compare the intensity of WNT7A expression in ovarian tumor specimens according to grade. Fisher's exact tests were used to determine up-regulation of WNT7A in each tumor subtype. Quantitative data were subjected to least-squares ANOVA and differences between individual means were tested by a Tukey multiple-range test using Prism 4.0 (Graphpad). Real-time PCR data were corrected for differences in sample loading using the RPL19 data as a covariate. Tests of significance were performed using the appropriate error terms according to the expectation of the mean squares for error. A p-value of 0.05 or less was considered significant. Data are presented as least-square means (LSM) with standard error of the means (SEM). Table S2 ). The levels of WNT3 and WNT4 were reduced by 82% and 85%, respectively (P<0.05), in malignant tissues. In contrast, WNT7A and WNT7B were overexpressed 398-fold and 34-fold, respectively (P<0.05), in malignant compared with normal ovarian tissues. WNT7A was selected for further analysis because it was the highest upregulated WNT ligand in malignant ovarian tissues.
Results
WNT7A is highly expressed in EOC
To determine the potential role of WNT7A in EOC, we first examined its spatial expression by radioactive in situ hybridization ( examination by a gynecological oncologist in this study revealed that WNT7A was detected only in the ovarian epithelium, not other cell types (Fig. 1a) .
WNT7A expression in ovarian cancer cell lines
Next, we determined relative WNT7A expression in a panel of ovarian carcinoma cell lines with variable tumorigenic potential (Supplemental Fig. 1a ). In agreement with data presented in Fig Because SKOV3.ip1 and SKOV3 are isogenic lines, we could examine the effects of naturally occurring WNT7A overexpression on transcriptional activation of genes known to be regulated by the WNT pathway. In particular, the expression of WNT7A, MMP7, and MMP9 was low in SKOV3 cells, but presented at high levels in SKOV3.ip1 cells. When mRNA levels in SKOV3 cells were set to a background level of 1, WNT7A, MMP7, and MMP9 were 390-, 3200-, and 5-fold, respectively, higher in SKOV3.ip1 cells (P<0.05, Supplemental Fig. 1b) . In contrast, WNT5A was expressed at equivalent levels in both SKOV3 and SKOV3.ip1 lines. This suggests that increased gene transcription of pro-metastatic MMP7, and MMP9 metalloproteinase genes might not be a general phenomenon, but rather a result of activation of a metastasis related transcriptional program in SKOV3.ip1 cells.
WNT7A regulates cell proliferation, adhesion and invasion of ovarian cancer cells
To understand the functional significance of WNT7A in ovarian cancer cells, we generated stable human ovarian cancer cell lines, in which WNT7A was either knocked down or overexpressed. To knockdown WNT7A and examine loss-of-function, SKOV3.ip1 cells, which have high endogenous WNT7A, were used in vitro following shRNA gene knockdown methods.
Two stable clones from #11 or #12 shRNA were selected based on puromycin resistance and western blot analysis of effective WNT7A knockdown. WNT7A was substantially depleted in clones #11 and #12 stably expressing WNT7A shRNAs compared with those infected with control shRNA (Fig. 2a) . Tumor cells with reduced expression of WNT7A also had lower expression of MMP7 and cyclin D1, suggesting that expression of both of these proteins is regulated by WNT7A signaling. To determine the effect of WNT7A overexpression, SKOV3 cells that lack endogenous WNT7A were transfected with empty vector or plasmids encoding WNT7A. Two G418-selected stable clones (B2 and E1) were used for further analysis based on WNT7A expression detected by western blot (Fig. 2a) . Once again, the expression of MMP7 and cyclin D1 mirrored upregulation of WNT7A in a genetically manipulated SKOV3 line.
Using these stable cell lines, we examined the in vitro effects of WNT7A on cell proliferation, adhesion and invasion, using these assays as indicators of WNT7A's role in tumor growth in vivo (Fig. 2b, c and d) . We confirmed that 13 of 19 WNT genes were expressed at low or undetectable levels in SKOV3 and HEY cells (Supplemental Fig. 2 To assess the potential role of WNT7A in cell dissemination into the peritoneal space and metastasis, we determined whether WNT7A affects cell adhesion and invasion of ovarian carcinoma cells. In solid-phase cell attachment assays (Fig. 2c) , we found that overexpression of 
WNT7A regulates tumor growth and progression in vivo
To determine the functional role of WNT7A on ovarian tumor growth, we injected nude mice i.p. with SKOV3.ip1 control or WNT7A knockdown cells (#11 or #12). After 5 weeks, we observed a significant difference in the pattern of tumor growth. Mice injected with control cells developed many large tumors in the omentum, abdominopelvic region, and numerous tumors studding the mesentery adjacent to the bowel (Fig. 3a) . Further, unmodified SKOV3.ip1 cells generated several tumor masses invading into the bowel as was determined upon histological examination (Fig. 3b) . The average number of tumor implants from injection of control cells was 61.3 ± 10.8, and total tumor weight was 863 ± 75 mg (Fig. 3c ). Mice injected with WNT7A knockdown cells typically developed only one large tumor in the retroperitoneal space (data not shown), but significantly fewer implants on the mesentery and abdominopelvic region than control (9.6 ± 3.5 implants, P<0.01 vs. control; Fig. 3a and c) . The total tumor weight was also Fig. 4b ). Moreover, significant differences were observed in cyclin D1 expression that was abundantly present in tumors from mice injected with control cells, but relatively low or absent in tumors generated by SKOV3.ip1 with WNT7A knockdown lines (Fig. 4c) .
Tumor growth regulated by WNT7A was confirmed by overexpression of WNT7A in SKOV3 cells after s.c. or i.p. implantation (Fig. 5) . Tumors derived from WNT7A overexpressing cells were significantly larger starting from day 20 (both B2 and E1), compared to empty vector control tumors (P<0.05; Fig. 5a, b and c) . Tumor weight at 9 weeks after s.c.
injection was higher by 7-fold (clone B2) or 12-fold (clone E1) in mice injected with WNT7A overexpressing cells (P<0.05; Fig. 5a and b). Cyclin D1 expression was also increased in tumors generated by SKOV3 with WNT7A overexpressing lines (Fig. 5d) . Although tumor growth and progression in the peritoneum was slower than that seen with SKOV3.ip1 cells, we did observe the presence of small tumors growing on the mesentery adjacent to the bowel in mice injected with WNT7A overexpressing cells 10 weeks after i.p. injection (Fig. 5e) . The number of implanted tumors in mice injected with WNT7A overexpressing cells (B2, 17.0 ± 4.5; E1, 39.7 ± 16.4 implants) were significantly higher in the mesentery and abdominopelvic region than those in vector control (1.3 ± 0.5 implants, P<0.05 vs. control; Fig. 5e ).
WNT7A activates the WNT/ȕ-catenin/TCF signaling pathway via FZD5
Next, we assessed whether WNT7A activates the ȕ-catenin-TCF/LEF signaling pathway, using transient transfection with an established TCF/LEF Top-Flash luciferase reporter (Fig. 6a) .
The TopFlash construct contains T-cell factor binding sites, which are directly activated by the T-cell factor/ȕ-catenin complex (34) (Fig. 6b) .
We also examined ȕ-catenin immunoreactivity in serous carcinomas using anti-active ȕ-catenin (clone 8E7) from Millipore (original from Upstate). The specificity of this antibody is amino acid residues 36-44 (HSGATTTAP) of human ȕ-catenin, Mr 92kDa, specific for the active form of ȕ-catenin dephosphorylated on Ser37 or Thr41. This antibody was used to determine the nuclear localization of ȕ-catenin (35) . We were able to detect nuclear ȕ-catenin in serous carcinomas (Supplemental Fig. 4 WNT7A expression by in situ hybridization and immunohistochemistry to detect nuclear ȕ-catenin were performed independently, 7 distinct cases of serous carcinomas were in common between the two arrays. Interestingly, 5 of 7 were strongly positive for both WNT7A and nuclear ȕ-catenin (Supplemental Fig. 4 ).
Because it has been noted in endometrioid ovarian carcinoma that CTNNB1 can be activated via constitutive mutations rather than activation of its normal signaling pathway (10).
We examined the mutation status in 25 serous carcinoma samples in which we detected nuclear localization of CTNNB1. We did not see evidence of mutations in the 3 "activation" hot spots 
WNT7A stimulates MMP7 promoter
To determine a downstream target of WNT7A signaling that can translate the effects of the ȕ-catenin pathway, we examined MMP7, which is an established WNT/ȕ-catenin target gene (7, 36) and one of the few MMP family members expressed in the epithelium (37, 38) . Robust MMP7 expression correlated with WNT7A expression levels in SKOV3.ip1 cells (Supplemental Fig. 1b) . MMP7 is a soluble metalloproteinase that has been repeatedly linked to tumor progression and metastasis in various types of cancers (39) . We, therefore, hypothesized that WNT7A-induced upregulation of MMP7 might confer a more aggressive growth phenotype in ovarian tumors in vivo. To test this hypothesis, we first examined whether WNT7A activates the MMP7 promoter in ovarian cancer cells. HEY cells were used for this study due to their low or undetectable levels of endogenous WNT7A and higher levels of endogenous MMP7 than those found in SKOV3 cells. Promoter activity was determined by comparing the relative luciferase activity from constructs containing different lengths of MMP7 5'-flanking sequences in transiently transfected HEY cells in the presence of WNT7A or control expression vectors (Fig.   7 ). Both the -535 and -204 nt promoter constructs expressed 2.3 and 2.5-fold, respectively, higher luciferase activity when WNT7A was overexpressed (P<0.05). This activation was specifically mediated by TCF binding sites because a shortened promoter lacking -204 to -62 segments with putative TCF sites (36) reduced the promoter's activity level to baseline (Fig. 7a   and b) . Furthermore, mutation of either of these TCF binding sites reduced luciferase activity by 69-76% (P<0.05) despite WNT7A overexpression (Fig. 7c) . Thus, these results provide the first molecular evidence that activation of ȕ-catenin-TCF/LEF signaling by WNT7A stimulates MMP7 promoter and increases MMP7 expression in ovarian cancer cells. 
Discussion
While the progression of cancer in general has been frequently attributed to constitutive activation of ȕ-catenin via WNT pathways (12, 31, 40) , the specific ligand partners associated with WNT signaling in ovarian cancer have not been identified. We postulate that WNT7A is one of the WNT ligands that can contribute to generation and formation of ovarian cancer in human patients. This conclusion is based on several pieces of evidence presented here. First, we found that WNT7A is abundantly expressed in ovarian malignant tumors, but absent in normal ovary. Second, we also found that WNT7A has the capacity to control cell division by altering cell cycle distribution, cell adhesion, and directional cell motility. Third, we showed in orthotopic ovarian xenograft models in vivo that WNT7A knockdown cancer cells have significantly decreased rate of growth, invasion and dissemination throughout the peritoneal cavity, and WNT7A overexpressing cells exhibit increased tumor growth. Fourth, we demonstrate here on a transcriptional level that WNT7A activates the canonical WNT/ȕ-catenin signaling pathway in ovarian cancer cells, and stimulates target genes that are critical for tumor growth and metastasis. Taken together, these findings suggest that WNT7A has an important role in the growth and progression of human ovarian malignancies.
Screening for the spatial expression of WNT7A in human specimens of ovarian cancer revealed that approximately 65% of serous adenocarcinomas expressed WNT7A with particularly strong expression. WNT7A upregulation has been reported in endometrial cancer (21) where its expression is exclusively restricted to epithelial cells (13) (14) (15) (16) 21) . Interestingly, WNT7A expression was not detected in the majority of endometrioid carcinomas, although mutations in ȕ-catenin are known to be present in more than 60% of ovarian endometrioid carcinomas and their precursor lesions (10, 41, 42) . It has been previously suggested that the formation of 
endometrioid carcinomas is promoted by ȕ-catenin mutations and constitutive activation of its downstream signaling (11, 43, 44) . However, nuclear localization of ȕ-catenin has been reported in not only endometrioid, but also serous carcinomas (12) . We show here that nuclear accumulation of ȕ-catenin in ovarian cancer cells is regulated by WNT7A. Thus, our studies support a novel mechanism promoting growth of serous carcinomas that might result from overstimulation of the intact ȕ-catenin pathway following overexpression of WNT7A.
The results from analysis of clinical specimens were consistent with the data derived from the xenograft models, further supporting the idea of WNT7A is a potential tumor promoting factor in EOC. Subcutaneously implanted SKOV3.ip1 tumors with suppressed WNT7A had a significantly slower growth rate concomitant with reduced expression of cyclin D1. These results were confirmed by overexpression of WNT7A as well. This finding suggests that WNT7A can promote cancer cell proliferation through alteration of cell cycle G 1 /S transition via accumulation of cyclin D1. It is well known that the relative expression pattern of cyclin D1 is critical for cell cycle progression (45) . Cyclin D1 expression is high during the G 0 /G 1 phase, allowing cells to enter S phase and replicate DNA, whereas its levels drop very low before rising again during G 2 (45) . In the present study, cyclin D1 levels paralleled those of WNT7A in overexpressed and knocked down cancer cells, and high expression of both proteins correlated with accumulation of cell populations in both the G 0 /G 1 and S phases. Thus, these results suggest that the control of cyclin D1 expression by WNT7A accelerates cell cycle in ovarian cancer cells, leading to increase proliferation noticed in both in vitro and in vivo settings.
In addition to increased proliferation, we found that WNT7A expression also affected the growth pattern of peritoneal lesions generated by SKOV3. We examined several downstream targets of WNT signaling that can translate the effects of the ȕ-catenin pathway into enhanced tumor growth and metastatic pattern observed in vivo.
One of the targets that attracted our attention was a metalloproteinase gene, MMP7, also known as matrilysin. MMP7 has been linked to activation of the ȕ-catenin pathway, and is well known to be associated with invasion and metastasis in a variety of cancers including those of stomach (46) , colon (47, 48) and pancreas (49) . MMP7 is one of the few MMP family members expressed in the epithelium, and promotes migration and invasion of tumor cells via extracellular cleavage of E-cadherin (37, 38) . MMP7 is also known to activate other MMPs, such as proMMP2 and proMMP9, which additionally facilitate tumor invasion (50). We found that 
